High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C: A multicentric, randomised, controlled trial

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 4, 2006, Pages 525-532

  Wartelle Bladou, Claire ^a   Arpurt, Jean Pierre ^b   Renou, Christophe ^c   Pariente, Alexandre ^d   Pillon, Didier ^e   Nalet, Bernard ^f   Picon, Magali ^a   Glibert, André ^g   Chousterman, Michel ^h   Grasset, Denis ⁱ   Morin, Thierry ^g   Bernard, Pierre ^j   Fischer, Daniel ^k   Ramdani, Mohamed ^l   Lagier, Evelyne ^a   Rotily, Michel ^m  

^a CENTRE HOSPITALIER DU PAYS D AIX   (France)

^b CENTRE HOSPITALIER D AVIGNON   (France)

^c Centre Hospitalier de Hyeres   (France)

^d CENTRE HOSPITALIER DE PAU   (France)

^e Emergency Department   (France)

^f Centre Hospitalier de Montélimar   (France)

^g Centre Hospitalier Intercommunal de Tarbes   (France)

^h Centre Hospitalier de Creteil   (France)

ⁱ Centre Hospitalier de Montauban   (France)

^j Centre Hospitalier Chalon sur Saone   (France)

^k Centre Hospitalier d'Evry   (France)

^l Centre Hospitalier Beziers   (France)

^m ClinSearch ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; TREATMENT WITHDRAWAL; VIRUS LOAD;

EID: 33744922172     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73221-3     Document Type: Article

References (25)

1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
2. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26: B303-20.
3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rutsgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
4. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
6. Fried MW, Shiffman M, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr., et al. Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
7. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):25-33.
8. Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, Garcia G, et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000;95:3225-9.
9. Hadziyannis AS, Papaioannou C, Spanou F, Manesis EK, Hadziyannis SJ. Induction interferon therapy in naive patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther 2001;15:551-7.
10. Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, et al. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group. J Hepatol 1998;29:224-32.
11. Larson AM, Rajvanshi P, Lee S, Polyak SJ, Gretch DR, Carithers Jr RL. High dose induction leads to improved sustained viral clearance in HCV genotype 1 patients. Hepatology 2001;34:336A.
12. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatits C. Hepatology 2001;34:1006-11.
13. Di Marco V, Ferraro D, Almasio P, Vaccaro A, Parisi P, Cappello M, et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. J Viral Hepatitis 2002;9:354-9.
14. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sönnerborg A, Weiland O, et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with or without ribavirin for chronic hepatitis C. Lancet 98;351:83-7.
15. Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337-41.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
17. Bellobuono A, Mondazzi L, Tempini S, Chiodo F, Magliano E, Furione L, et al. Early addition of ribavirin to interferon in chronic hepatitis C non responsive to interferon monotherapy. J Hepatol 2000;33:463-8.
18. Lunel F, Veillon P, Fouchard-Hubert I, Loustaud-ratti V, Abergel A, Silvain C, et al. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. J Hepatol 2003;39:826-33.
19. Herrmann E, Lee JH, Marinos G, Modi M Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351-8.
20. Reichard O, Yun ZB, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatits C. J Med Virol 1993;41:99-102.
21. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
22. Pawlotsky JM, Dahari H, Neumann AU, Hézode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703-14.
23. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
24. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002;24:1363-83.
25. Glue P, Fang J, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interfero-alpha 2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatitis C intervention therapy group. Clin Pharmacol Ther 2000;68:556-67.